Positions

Overview

  • Dr. Birrer earned his undergraduate degree at Rensselaer Polytechnic Institute and graduated with a BS in Biology. He subsequently was accepted into the Medical Scientist Training Program at the Albert Einstein College of Medicine and completed his M.D. and Ph.D. in 1982 with his principle area of study in microbiology and immunology. He performed a medical internship at the Massachusetts General Hospital (MGH) and subsequently completed a residency in medicine at MGH. Dr. Birrer entered the medical oncology fellowship at the National Cancer Institute in Bethesda, Maryland and upon completion performed a postdoctoral fellowship in the laboratory of Dr. John Minna on the molecular genetics of lung cancer. After completing his fellowship, Dr. Birrer joined the faculty at the NCI in the Division of Cancer Treatment as an investigator in 1988. Three years later, Dr. Birrer was appointed as a senior investigator (with tenure) and established the molecular mechanism section in the Division of Cancer Prevention and Control. Over the next 17 years, Dr. Birrer held a number of positions including the Committee for the Protection of Human Subjects, Gynecologic Oncology Tumor Board, Extramural IRB, Clinical Oncology Fellowship Section Committee, Chair of the Gynecologic Oncology Working Group in the Division of Clinical Sciences and Deputy Branch Chief of the Cell and Cancer Biology Branch.

    Dr. Birrer is recognized nationally and internationally as an expert in gynecologic oncology. He has published over 270 peer reviewed manuscripts and another 27 book chapters and review articles. He has served in leadership positions within the greater gynecologic oncology community. He has been the Chair and Chair Emeritus of the DOD Ovarian Cancer Research Program, Chair of the Committee for Experimental Medicine of the Gynecologic Oncology Group, a member of the Gynecologic Cancer Steering Committee and Chair of the Translational Science Working Group of the Gynecologic Cancer Intergroup. Dr. Birrer has been a member of the Society of Gynecologic Oncology, American Society of Clinical Oncologists, American Association of Cancer Research and the International Gynecologic Cancer Society. He has been on the program committees of ASCO, SGO and IGCS.

    In November 2008, Dr. Birrer was appointed Professor of Medicine at the Harvard School of Medicine. Dr. Birrer assumed the position of Director of Gynecologic Medical Oncology at MGH and the Gynecologic Oncology Research Program. This program integrates important new discoveries in translational research into clinical trials.

    In August 2017, Dr. Birrer accepted the position of Director of the Comprehensive Cancer Center at the University of Alabama at Birmingham. He is a Professor of Medicine in the Division of Hematology-Oncology and holds the Evalina B. Spencer Chair in Oncology.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2019 Methods for Systematic Identification of Membrane Proteins for Specific Capture of Cancer-Derived Extracellular VesiclesCell Reports.  27:255-268.e6. 2019
    2019 Is Targeting the Folate Receptor in Ovarian Cancer Coming of Age?Oncologist.  24:425-429. 2019
    2019 Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trialLancet Oncology.  20:570-580. 2019
    2019 Variation in resource utilization associated with the surgical management of ovarian cancerGynecologic Oncology.  152:587-593. 2019
    2019 Evaluation of prophylactic corticosteroid eye drop use in the management of corneal abnormalities induced by the antibody–drug conjugate mirvetuximab soravtansineClinical Cancer Research.  25:1727-1736. 2019
    2019 Final report on serial phase II trials of all-intraperitoneal chemotherapy with or without bevacizumab for women with newly diagnosed, optimally cytoreduced carcinoma of Müllerian originGynecologic Oncology2019
    2019 GOG 8020/210: Risk stratification of lymph node metastasis, disease progression and survival using single nucleotide polymorphisms in endometrial cancer: An NRG oncology/gynecologic oncology group studyGynecologic Oncology2019
    2018 ISG15 promotes ERK1 ISGylation, CD8+ T cell activation and suppresses ovarian cancer progressionCancers.  10. 2018
    2018 Primordial germ cells as a potential shared cell of origin for mucinous cystic neoplasms of the pancreas and mucinous ovarian tumorsJournal of Pathology.  246:459-469. 2018
    2018 Comprehensive Molecular Characterization of the Hippo Signaling Pathway in CancerCell Reports.  25:1304-1317.e5. 2018
    2018 A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-β SuperfamilyCell Systems.  7:422-437.e7. 2018
    2018 Consensus on molecular subtypes of high-grade serous ovarian carcinomaClinical Cancer Research.  24:5037-5047. 2018
    2018 Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancerGynecologic Oncology.  151:46-52. 2018
    2018 Integrative kinome profiling identifies mTORC1/2 inhibition as treatment strategy in ovarian clear cell CarcinomaClinical Cancer Research.  24:3928-3940. 2018
    2018 Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 PatientsCancer Cell.  34:211-224.e6. 2018
    2018 Erratum: Comprehensive Characterization of Cancer Driver Genes and Mutations (ARTICLE (2018) 173(2) (371–385), (S009286741830237X), (10.1016/j.cell.2018.02.060))Cell.  174:1034-1035. 2018
    2018 FORWARD I: A Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancerFuture Oncology.  14:1669-1678. 2018
    2018 Erratum: The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma (Cell Reports (2018) 23(1) (313–326.e5) (S2211124718304364) (10.1016/j.celrep.2018.03.075))Cell Reports.  23:3698. 2018
    2018 Phase I study of MEDI3617, a selective angiopoietin-2 inhibitor alone and combined with carboplatin/paclitaxel, paclitaxel, or bevacizumab for advanced solid tumorsClinical Cancer Research.  24:2749-2757. 2018
    2018 Administration of the Tablet Formulation of Olaparib in Patients with Ovarian Cancer: Practical Guidance and ExpectationsOncologist.  23:697-703. 2018
    2018 Complete Remission Following Pembrolizumab in a Woman with Mismatch Repair-Deficient Endometrial Cancer and a Germline BRCA1 MutationOncologist.  23:650-653. 2018
    2018 The Immune Landscape of CancerImmunity.  48:812-830.e14. 2018
    2018 A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast CancersCancer Cell.  33:690-705.e9. 2018
    2018 Comparative Molecular Analysis of Gastrointestinal AdenocarcinomasCancer Cell.  33:721-735.e8. 2018
    2018 Genomic and Functional Approaches to Understanding Cancer AneuploidyCancer Cell.  33:676-689.e3. 2018
    2018 lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in CancerCancer Cell.  33:706-720.e9. 2018
    2018 A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient SamplesCell.  173:386-399.e12. 2018
    2018 An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome AnalyticsCell.  173:400-416.e11. 2018
    2018 Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of CancerCell.  173:291-304.e6. 2018
    2018 Comprehensive Characterization of Cancer Driver Genes and MutationsCell.  173:371-385.e18. 2018
    2018 Machine Learning Identifies Stemness Features Associated with Oncogenic DedifferentiationCell.  173:338-354.e15. 2018
    2018 Oncogenic Signaling Pathways in The Cancer Genome AtlasCell.  173:321-337.e10. 2018
    2018 Pathogenic Germline Variants in 10,389 Adult CancersCell.  173:355-370.e14. 2018
    2018 Perspective on Oncogenic Processes at the End of the Beginning of Cancer GenomicsCell.  173:305-320.e10. 2018
    2018 Driver Fusions and Their Implications in the Development and Treatment of Human CancersCell Reports.  23:227-238.e3. 2018
    2018 Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome AtlasCell Reports.  23:239-254.e6. 2018
    2018 Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous CarcinomasCell Reports.  23:194-212.e6. 2018
    2018 Integrated Genomic Analysis of the Ubiquitin Pathway across Cancer TypesCell Reports.  23:213-226.e3. 2018
    2018 Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome AtlasCell Reports.  23:172-180.e3. 2018
    2018 Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human CancersCell Reports.  23:255-269.e4. 2018
    2018 Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor ContextCell Reports.  23:297-312.e12. 2018
    2018 Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer TypesCell Reports.  23:282-296.e4. 2018
    2018 Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology ImagesCell Reports.  23:181-193.e7. 2018
    2018 Systematic Analysis of Splice-Site-Creating Mutations in CancerCell Reports.  23:270-281.e3. 2018
    2018 The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell CarcinomaCell Reports.  23:313-326.e5. 2018
    2018 Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II studyAnnals of Oncology.  29:917-923. 2018
    2018 Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome AtlasCell Systems.  6:282-300.e2. 2018
    2018 Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic PipelinesCell Systems.  6:271-281.e7. 2018
    2018 Mutations in homologous recombination genes and outcomes in ovarian carcinoma patients in GOG 218: An NRG oncology/Gynecologic oncology group studyClinical Cancer Research.  24:777-783. 2018
    2018 Erratum: Publisher Correction: Nanoparticle conjugates of a highly potent toxin enhance safety and circumvent platinum resistance in ovarian cancer (Nature communications (2017) 8 1 (2166))Nature Communications.  9:628. 2018
    2018 Cancer-associated fibroblasts regulate endothelial adhesion protein LPP to promote ovarian cancer chemoresistanceJournal of Clinical Investigation.  128:589-606. 2018
    2018 Clinicopathologic characteristics associated with long-term survival in advanced epithelial ovarian cancer: an NRG Oncology/Gynecologic Oncology Group ancillary data studyGynecologic Oncology.  148:275-280. 2018
    2018 A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancerFuture Oncology.  14:123-136. 2018
    2017 Differential Effects of EGFL6 on Tumor versus Wound AngiogenesisCell Reports.  21:2785-2795. 2017
    2017 Dysregulation of miR-181c expression influences recurrence of endometrial endometrioid adenocarcinoma by modulating NOTCH2 expression: An NRG Oncology/Gynecologic Oncology Group studyGynecologic Oncology.  147:648-653. 2017
    2017 Nanoparticle conjugates of a highly potent toxin enhance safety and circumvent platinum resistance in ovarian cancerNature Communications.  8. 2017
    2017 Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue SarcomasCell.  171:950-965.e28. 2017
    2017 An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experienceGynecologic Oncology.  147:243-249. 2017
    2017 Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansineGynecologic Oncology.  147:402-407. 2017
    2017 Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced stage serous ovarian or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group studyGynecologic Oncology.  147:396-401. 2017
    2017 How can molecular abnormalities influence our clinical approachAnnals of Oncology.  28:viii16-viii24. 2017
    2017 Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker AnalysesJNCI: Journal of the National Cancer Institute.  109. 2017
    2017 Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trialLancet.  390:1949-1961. 2017
    2017 Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)Lancet.  390:1654-1663. 2017
    2017 Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumorsCancer.  123:3080-3087. 2017
    2017 High stathmin expression is a marker for poor clinical outcome in endometrial cancer: An NRG oncology group/gynecologic oncology group studyGynecologic Oncology.  146:247-253. 2017
    2017 Early tumor detection afforded by in vivo imaging of near-infrared II fluorescenceBiomaterials.  134:202-215. 2017
    2017 Multiplex profiling identifies distinct local and systemic alterations during intraperitoneal chemotherapy for ovarian cancer: An NRG Oncology/Gynecologic Oncology Group StudyGynecologic Oncology.  146:137-145. 2017
    2017 Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancerNature Genetics.  49:680-691. 2017
    2017 Safety and activity of mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: A phase i expansion studyJournal of Clinical Oncology.  35:1112-1118. 2017
    2017 Integrated genomic and molecular characterization of cervical cancerNature.  543:378-384. 2017
    2017 Maximizing Synergistic Activity When Combining RNAi and Platinum-Based Anticancer AgentsJournal of the American Chemical Society.  139:3033-3044. 2017
    2017 ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cellsGenes and Development.  31:318-332. 2017
    2017 A phase II evaluation of ixabepilone in the treatment of recurrent/persistent carcinosarcoma of the uterus, an NRG Oncology/Gynecologic Oncology Group studyGynecologic Oncology.  144:101-106. 2017
    2017 Extended carboplatin infusion does not reduce frequency of hypersensitivity reaction at initiation of retreatment in patients with recurrent platinum-sensitive ovarian cancerJournal of Allergy and Clinical Immunology: In Practice.  5:177-178. 2017
    2017 Integrated genomic analysis of clear cell ovarian cancers identified PRKCI as a potential therapeutic targetOncotarget.  8:96482-96495. 2017
    2017 Outcomes of women with high-grade and low-grade advanced-stage serous epithelial ovarian cancerObstetrics and Gynecology.  129:439-447. 2017
    2017 Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancerAnnals of Oncology.  28:512-518. 2017
    2016 Phase 1 and 2 study of carboplatin and pralatrexate in patients with recurrent, platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancerCancer.  122:3297-3306. 2016
    2016 Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancerAnnals of Oncology.  27:2124-2130. 2016
    2016 “Carcinosarcoma of the ovary, fallopian tube, and peritoneum: Prognostic factors and treatment modalities”Gynecologic Oncology.  142:248-254. 2016
    2016 Chemotherapy-induced nausea and vomitingNew England Journal of Medicine.  375:177-179. 2016
    2016 A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancerGynecologic Oncology.  142:62-69. 2016
    2016 CD44 splice variant v8-10 as a marker of serous ovarian cancer prognosisPLoS ONE.  11. 2016
    2016 Making a Difference: Distinguishing Two Primaries from Metastasis in Synchronous Tumors of the Ovary and UterusJNCI: Journal of the National Cancer Institute.  108. 2016
    2016 Phase 1 Study of Monotherapy with KHK2866, an Anti-Heparin-Binding Epidermal Growth Factor-Like Growth Factor Monoclonal Antibody, in Patients with Advanced CancerTargeted Oncology.  11:317-327. 2016
    2016 Weekly Versus Every-3-Week Paclitaxel and Carboplatin for Ovarian CancerObstetrical and Gynecological Survey.  71:344-345. 2016
    2016 A SNaPshot of potentially personalized care: Molecular diagnostics in gynecologic cancerGynecologic Oncology.  141:108-112. 2016
    2016 Epithelial ovarian cancer: The molecular genetics of epithelial ovarian cancerAnnals of Oncology.  27:i4-i10. 2016
    2016 Inherited mutations in women with ovarian carcinomaJAMA Oncology.  2:482-490. 2016
    2016 Targeting the nuclear import receptor Kpnβ1 as an anticancer therapeuticMolecular Cancer Therapeutics.  15:560-573. 2016
    2016 Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group studyGynecologic Oncology.  141:43-48. 2016
    2016 Somatic mosaic mutations in PPM1D and TP53 in the blood of women with ovarian carcinomaJAMA Oncology.  2:370-372. 2016
    2016 Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancerNew England Journal of Medicine.  374:738-748. 2016
    2016 The doppelganger effect: Hidden duplicates in databases of transcriptome profilesJNCI: Journal of the National Cancer Institute.  108. 2016
    2015 Erratum: Common variants at 19p13 are associated with susceptibility to ovarian cancer (Nature Genetics (2010) 42 (880-884))Nature Genetics.  48:101. 2015
    2015 Sustained, low-dose intraperitoneal cisplatin improves treatment outcome in ovarian cancer mouse modelsJournal of Controlled Release.  220:358-367. 2015
    2015 Creation of a human secretome: A novel composite library of human secreted proteins: Validation using ovarian cancer gene expression data and a virtual secretome arrayClinical Cancer Research.  21:4960-4969. 2015
    2015 AAV9 delivering a modified human Mullerian inhibiting substance as a gene therapy in patient-derived xenografts of ovarian cancerProceedings of the National Academy of Sciences.  112:E4418-E4427. 2015
    2015 Comparing platforms for messenger RNA expression profiling of archival formalin-fixed, paraffin-embedded tissuesJournal of Molecular Diagnostics.  17:374-381. 2015
    2015 Translational impact of nanoparticle-drug conjugate CRLX101 with or without bevacizumab in advanced ovarian cancerClinical Cancer Research.  21:808-818. 2015
    2015 A functional variant in HOXA 11-AS, a novel long non-coding RNA, inhibits the oncogenic phenotype of epithelial ovarian cancerOncotarget.  6:34745-34757. 2015
    2015 Advances in the management of recurrent endometrial cancerAmerican Journal of Clinical Oncology.  38:206-212. 2015
    2015 Connective tissue growth factor as a novel therapeutic target in high grade serous ovarian cancerOncotarget.  6:44551-44562. 2015
    2015 Erratum to Elagib et al., Jun Blockade of erythropoiesis: Role for repression of GATA-1 by HERP2 [Mol Cell Biol. 24, 17, (2004), 7779-7794]Molecular and Cellular Biology.  35:2215-2215. 2015
    2015 Exploring alternative ovarian cancer biomarkers using innovative nanotechnology strategiesCancer and Metastasis Reviews.  34:75-82. 2015
    2015 Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinomaGynecologic Oncology.  136:246-253. 2015
    2015 Rethinking ovarian cancer II: Reducing mortality from high-grade serous ovarian cancerNature Reviews Cancer.  15:668-679. 2015
    2015 Spleen Tyrosine Kinase Confers Paclitaxel Resistance in Ovarian CancerCancer Cell.  28:7-9. 2015
    2014 Deep, noninvasive imaging and surgical guidance of submillimeter tumors using targeted M13-stabilized single-walled carbon nanotubesProceedings of the National Academy of Sciences.  111:13948-13953. 2014
    2014 Deep, noninvasive imaging and surgical guidance of submillimeter tumors using targeted M13-stabilized single-walled carbon nanotubesProceedings of the National Academy of Sciences.  111:13948-13953. 2014
    2014 FOXO3a loss is a frequent early event in high-grade pelvic serous carcinogenesisOncogene.  33:4424-4432. 2014
    2014 Identification of LMX1B as a novel oncogene in human ovarian cancerOncogene.  33:4226-4235. 2014
    2014 Comparative meta-analysis of prognostic gene signatures for late-stage ovarian cancerJNCI: Journal of the National Cancer Institute.  106. 2014
    2014 Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samplesJNCI: Journal of the National Cancer Institute.  106. 2014
    2014 Activation of YAP1 is associated with poor prognosis and response to taxanes in ovarian cancerAnticancer Research.  34:811-818. 2014
    2014 Advances in the diagnosis and treatment of uterine sarcomasDiscovery medicine.  17:339-345. 2014
    2014 Better therapeutic trials in ovarian cancerJNCI: Journal of the National Cancer Institute.  106. 2014
    2014 Calcium dependent FAK/CREB/TNNC1 signaling mediates the effect of stromal MFAP5 on ovarian cancer metastatic potentialNature Communications.  5. 2014
    2014 Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: A randomised phase 2 studyLancet Oncology.  15:1207-1214. 2014
    2014 FOXO3a loss is a frequent early event in high-grade pelvic serous carcinogenesisOncogene.  33:4424-4432. 2014
    2014 Loss of LKB1 and PTEN tumor suppressor genes in the ovarian surface epithelium induces papillary serous ovarian cancerCarcinogenesis.  35:546-553. 2014
    2014 Molecular subtypes of high-grade serous ovarian cancer: The holy grail?JNCI: Journal of the National Cancer Institute.  106. 2014
    2014 Ovarian cancer: targeting the untargetableAmerican Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting.  13-15. 2014
    2013 Ascites analysis by a microfluidic chip allows tumor-cell profilingProceedings of the National Academy of Sciences.  110. 2013
    2013 Ovarian cancer: Genomic analysisAnnals of Oncology.  24. 2013
    2013 curatedOvarianData: Clinically annotated data for the ovarian cancer transcriptomeDatabase : the Journal of Biological Databases and Curation.  2013. 2013
    2013 Gynecologic cancer intergroup (GCIG) endometrial cancer clinical trials planning meeting: Taking endometrial cancer trials into the translational eraInternational Journal of Gynecological Cancer.  23:1528-1534. 2013
    2013 FGF18 as a prognostic and therapeutic biomarker in ovarian cancerJournal of Clinical Investigation.  123:4435-4448. 2013
    2013 A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancerEuropean Journal of Cancer.  49:2972-2978. 2013
    2013 Patterns of recurrence in patients treated with bevacizumab in the primary treatment of advanced epithelial ovarian cancerInternational Journal of Gynecological Cancer.  23:1219-1225. 2013
    2013 TGF-β Modulates ovarian cancer invasion by upregulating CAF-Derived versican in the tumor microenvironmentCancer Research.  73:5016-5028. 2013
    2013 p21-Activated Kinase 3 (PAK3) Is an AP-1 Regulated Gene Contributing to Actin Organisation and Migration of Transformed FibroblastsPLoS ONE.  8. 2013
    2013 Integrated genomic characterization of endometrial carcinomaNature.  497:67-73. 2013
    2013 Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31Nature Communications.  4. 2013
    2013 BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: A Gynecologic Oncology Group StudyBritish Journal of Cancer.  108:1231-1237. 2013
    2013 GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancerNature Genetics.  45:362-370. 2013
    2013 Low-grade and high-grade serous Mullerian carcinoma: Review and analysis of publicly available gene expression profilesGynecologic Oncology.  128:488-492. 2013
    2013 Identification of FGFR4 as a potential therapeutic target for advanced-stage, high-grade serous ovarian cancerClinical Cancer Research.  19:809-820. 2013
    2013 Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: An open-label, Single-arm, Phase 2 studyLancet Oncology.  14:134-140. 2013
    2013 Inherited Variants in Regulatory T Cell Genes and Outcome of Ovarian CancerPLoS ONE.  8. 2013
    2013 Prognostically relevant gene signatures of high-grade serous ovarian carcinomaJournal of Clinical Investigation.  123:517-525. 2013
    2013 Clear cell cancer of the ovaryCurrent Opinion in Oncology.  25:553-557. 2013
    2012 Uterine papillary serous cancer: A review of the literatureGynecologic Oncology.  127:651-661. 2012
    2012 SUZ12 promotes human epithelial ovarian cancer by suppressing apoptosis via silencing HRKCell Growth and Differentiation.  10:1462-1472. 2012
    2012 An RNA Interference Lethality Screen of the Human Druggable Genome to Identify Molecular Vulnerabilities in Epithelial Ovarian CancerPLoS ONE.  7. 2012
    2012 Clear cell carcinoma of the ovary: A review of the literatureGynecologic Oncology.  126:481-490. 2012
    2012 BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: A report from the Australian ovarian cancer study groupJournal of Clinical Oncology.  30:2654-2663. 2012
    2012 Reclassification of serous ovarian carcinoma by a 2-tier system: A Gynecologic Oncology Group studyCancer.  118:3087-3094. 2012
    2012 Incorporation of bevacizumab in the primary treatment of ovarian cancerObstetrical and Gynecological Survey.  67:289-290. 2012
    2012 Pre-treatment tumor expression of ERCC1 in women with advanced stage epithelial ovarian cancer is not predictive of clinical outcomes: A gynecologic oncology group studyGynecologic Oncology.  125:421-426. 2012
    2012 Carcinosarcoma of the ovary: A review of the literatureGynecologic Oncology.  125:271-277. 2012
    2012 ALDH1A1 is a novel EZH2 target gene in epithelial ovarian cancer identified by genome-wide approachesCancer Prevention Research.  5:484-491. 2012
    2012 Common variation in nemo-like kinase is associated with risk of ovarian cancerCancer Epidemiology, Biomarkers and Prevention.  21:523-528. 2012
    2012 Ovarian cancer risk associated with inherited inflammation- related variantsCancer Research.  72:1064-1069. 2012
    2012 Genome wide DNA copy number analysis of serous type ovarian carcinomas identifies genetic markers predictive of clinical outcomePLoS ONE.  7. 2012
    2012 Multi-gene expression predictors of single drug responses to adjuvant chemotherapy in ovarian carcinoma: Predicting platinum resistancePLoS ONE.  7. 2012
    2012 Identification of a potential ovarian cancer stem cell gene expression profile from advanced stage papillary serous ovarian cancerPLoS ONE.  7. 2012
    2011 Incorporation of bevacizumab in the primary treatment of ovarian cancerNew England Journal of Medicine.  365:2473-2483. 2011
    2011 CON: Patients at high risk for ovarian cancer should not undergo routine screeningClinical Ovarian Cancer.  4:86-89. 2011
    2011 CON: Therapy for a patient with platinumresistant/refractory ovarian cancer should not be selected based on results of an in vitro extreme drug sensitivity/resistance assayClinical Ovarian Cancer.  4:57-61. 2011
    2011 PRO: Patients with recurrent ovarian cancer should be treated with antiangiogenic agents in combination with chemotherapyClinical Ovarian Cancer.  4:70-73. 2011
    2011 Inhibition of hedgehog signaling antagonizes serous ovarian cancer growth in a primary xenograft modelPLoS ONE.  6. 2011
    2011 Wnt5a suppresses epithelial ovarian cancer by promoting cellular senescenceCancer Research.  71:6184-6194. 2011
    2011 CXCL12/CXCR4 blockade induces multimodal antitumor effects that prolong survival in an immunocompetent mouse model of ovarian cancerCancer Research.  71:5522-5534. 2011
    2011 Tissue-based immune monitoring I: Tumor core needle biopsies allow in-depth interrogation of the tumor microenvironmentCancer Biology and Therapy.  12:357-366. 2011
    2011 Tissue-based immune monitoring II: Multiple tumor sites reveal immunologic homogeneity in serous ovarian carcinomaCancer Biology and Therapy.  12:367-377. 2011
    2011 MicroRNA processing and binding site polymorphisms are not replicated in the Ovarian Cancer Association ConsortiumCancer Epidemiology, Biomarkers and Prevention.  20:1793-1797. 2011
    2011 Identification of novel therapeutic targets in microdissected clear cell ovarian cancersPLoS ONE.  6. 2011
    2011 Integrated genomic analyses of ovarian carcinomaNature.  474:609-615. 2011
    2011 LIN28B polymorphisms influence susceptibility to epithelial ovarian cancerCancer Research.  71:3896-3903. 2011
    2011 The anterior gradient homolog 3 (AGR3) gene is associated with differentiation and survival in ovarian cancerAmerican Journal of Surgical Pathology.  35:904-912. 2011
    2011 The role of KRAS rs61764370 in invasive epithelial ovarian cancer: Implications for clinical testingClinical Cancer Research.  17:3742-3750. 2011
    2011 Inhibition of AP-1 suppresses cervical cancer cell proliferation and is associated with p21 expressionBiological Chemistry.  392:439-448. 2011
    2011 Minichromosome maintenance (MCM) protein 4 as a marker for proliferation and its clinical and clinicopathological significance in non-small cell lung cancerLung Cancer.  72:229-237. 2011
    2011 Nuclear P27 expression in benign, borderline (LMP) and invasive tumors of the ovary and its association with prognosis: A gynecologic oncology group studyGynecologic Oncology.  121:395-401. 2011
    2011 Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: A Gynecologic Oncology Group studyGynecologic Oncology.  121:303-308. 2011
    2011 Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancersPLoS ONE.  6. 2011
    2011 IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancerClinical Cancer Research.  17:2538-2548. 2011
    2011 Integrated analysis of multiple microarray datasets identifies a reproducible survival predictor in ovarian cancerPLoS ONE.  6. 2011
    2011 Comparison of expression profiles in ovarian epithelium in vivo and ovarian cancer identifies novel candidate genes involved in disease pathogenesisPLoS ONE.  6. 2011
    2011 Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: A Gynecologic Oncology Group trialJournal of Clinical Oncology.  29:69-75. 2011
    2010 A polymorphism in the GALNT2 gene and ovarian cancer risk in four population based case-control studiesInternational Journal of Molecular Epidemiology and Genetics.  1:272-277. 2010
    2010 ResponseJNCI: Journal of the National Cancer Institute.  102:1741-1742. 2010
    2010 The origin of ovarian cancer - Is it getting clearer?New England Journal of Medicine.  363:1574-1575. 2010
    2010 A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24Nature Genetics.  42:874-879. 2010
    2010 Common variants at 19p13 are associated with susceptibility to ovarian cancerNature Genetics.  42:880-884. 2010
    2010 Up-regulation of stromal versican expression in advanced stage serous ovarian cancerGynecologic Oncology.  119:114-120. 2010
    2010 Editorial: CD157 in ovarian carcinoma: How does it help us?JNCI: Journal of the National Cancer Institute.  102:1004-1005. 2010
    2010 Regulation of tumor angiogenesis by EZH2Cancer Cell.  18:185-197. 2010
    2010 Nuclear factor κB transcription factors are coexpressed and convey a poor outcome in ovarian cancerCancer.  116:3276-3284. 2010
    2010 Ovarian cancer: Individualized and personalized careExpert Review of Obstetrics and Gynecology.  5:409-419. 2010
    2010 Translational research in the Gynecologic Oncology Group: Evaluation of ovarian cancer markers, profiles, and novel therapiesGynecologic Oncology.  117:429-439. 2010
    2010 Activation of NF-κB signaling by inhibitor of NF-κB kinase β increases aggressiveness of ovarian cancerCancer Research.  70:4005-4014. 2010
    2010 Efficacy and safety of imatinib mesylate (Gleevec®) and immunohistochemical expression of c-Kit and PDGFR-β in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterusGynecologic Oncology.  117:248-254. 2010
    2010 Personalizing therapy for ovarian cancerTherapy.  7:229-239. 2010
    2010 FGFR2 mutations are rare across histologic subtypes of ovarian cancerGynecologic Oncology.  117:125-129. 2010
    2010 NIH and NCI support for development of novel therapeutics in gynecologic cancer: A user's guideGynecologic Oncology.  116:177-180. 2010
    2010 Chemotherapy intensity and toxicity among black and white women with advanced and recurrent endometrial cancer: A gynecologic oncology group studyCancer.  116:355-361. 2010
    2010 Current academic clinical trials in ovarian cancer: Gynecologic cancer intergroup and us national cancer institute clinical trials planning meeting, may 2009International Journal of Gynecological Cancer.  20:1. 2010
    2010 Current challenges and future directions in the management of ovarian cancer: Proceedings of the first global workshop on ovarian cancerClinical Ovarian Cancer.  3:81-97. 2010
    2010 Overexpression of elafin in ovarian carcinoma is driven by genomic gains and activation of the nuclear factor κB pathway and is associated with poor overall survivalNeoplasia : An International Journal for Oncology Research.  12:161-172. 2010
    2010 The Gynecologic Oncology Group ovarian treatment trials with specimen banking and translational researchClinical Ovarian Cancer.  3:98-112. 2010
    2009 A Gene Signature Predictive for Outcome in Advanced Ovarian Cancer Identifies a Survival Factor: Microfibril-Associated Glycoprotein 2Cancer Cell.  16:521-532. 2009
    2009 Novel Therapeutic TargetsCancer Treatment and Research.  149:63-84. 2009
    2009 Race does not impact outcome for advanced ovarian cancer patients treated with cisplatin/paclitaxel: Analysis of Gynecologic Oncology Group TrialsCancer.  115:4210-4217. 2009
    2009 Prognostic relevance of c-MYC gene amplification and polysomy for chromosome 8 in suboptimally-resected, advanced stage epithelial ovarian cancers: A Gynecologic Oncology Group studyGynecologic Oncology.  114:472-479. 2009
    2009 Associations between ERBB2 amplification and progression-free survival and overall survival in advanced stage, suboptimally-resected epithelial ovarian cancers: A Gynecologic Oncology Group studyGynecologic Oncology.  113:341-347. 2009
    2009 NORE1A tumor suppressor candidate modulates p21CIP1 via p53Cancer Research.  69:4629-4637. 2009
    2009 A key role for early growth response-1 and nuclear factor-κB in mediating and maintaining GRO/CXCR2 proliferative signaling in esophageal cancerCell Growth and Differentiation.  7:755-764. 2009
    2009 Calcineurin activates cytoglobin transcription in hypoxic myocytesJournal of Biological Chemistry.  284:10409-10421. 2009
    2009 The karyopherin proteins, Crm1 and Karyopherin β1, are overexpressed in cervical cancer and are critical for cancer cell survival and proliferationInternational Journal of Cancer.  124:1829-1840. 2009
    2009 Dysregulated microRNAs and their predicted targets associated with endometrioid endometrial adenocarcinoma in Hong Kong womenInternational Journal of Cancer.  124:1358-1365. 2009
    2009 Debate: Treatment of patients with recurrent ovarian cancer should be treated with antiangiogenic agents in combination with chemotherapyClinical Ovarian Cancer.  2:12-15. 2009
    2009 Editorial: Getting personal: The treatment of epithelial ovarian cancerClinical Ovarian Cancer.  2:9-11. 2009
    2009 Inflammatory cytokine tumor necrosis factor α confers precancerous phenotype in an organoid model of normal human ovarian surface epithelial cellsNeoplasia : An International Journal for Oncology Research.  11:529-541. 2009
    2009 Inhibition of AP-1 transcriptional activity blocks the migration, invasion, and experimental metastasis of murine osteosarcomaAmerican Journal of Pathology.  174:265-275. 2009
    2009 Matrilysin-1 mediates bronchiolization of alveoli, a potential premalignant change in lung cancerAmerican Journal of Pathology.  175:592-604. 2009
    2009 Ovarian cancer: markers of response.International Journal of Gynecological Cancer.  19 Suppl 2. 2009
    2009 Validation of serum biomarkers for detection of early-stage ovarian cancerAmerican Journal of Obstetrics and Gynecology.  200:639.e1-639.e5. 2009
    2008 Dicer, Drosha, and outcomes in patients with ovarian cancerNew England Journal of Medicine.  359:2641-2650. 2008
    2008 Simultaneous blockade of AP-1 and phosphatidylinositol 3-kinase pathway in non-small cell lung cancer cellsBritish Journal of Cancer.  99:2013-2019. 2008
    2008 Increased HLA-DMB expression in the tumor epithelium is associated with increased CTL infiltration and improved prognosis in advanced-stage serous ovarian cancerClinical Cancer Research.  14:7667-7673. 2008
    2008 Egr1 regulates the coordinated expression of numerous EGF receptor target genes as identified by ChIP-on-chipGenome Biology.  9. 2008
    2008 Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumorsCell Growth and Differentiation.  6:1678-1690. 2008
    2008 Asparagine synthetase is a predictive biomarker of L-asparaginase activity in ovarian cancer cell linesMolecular Cancer Therapeutics.  7:3123-3128. 2008
    2008 Classification of ovarian cancer: a genomic analysis.Advances in Experimental Medicine and Biology.  622:23-33. 2008
    2008 A gene signature predicting for survival in suboptimally debulked patients with ovarian cancerCancer Research.  68:5478-5486. 2008
    2008 Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancerProceedings of the National Academy of Sciences.  105:7004-7009. 2008
    2008 Genomic analysis of epithelial ovarian cancerCell Research.  18:538-548. 2008
    2008 Overexpression of CEACAM6 in borderline and invasive mucinous ovarian neoplasmsGynecologic Oncology.  109:234-239. 2008
    2008 Growth inhibition of non-small cell lung cancer cells by AP-1 blockade using a cJun dominant-negative mutantBritish Journal of Cancer.  98:915-922. 2008
    2008 Early events in the pathogenesis of epithelial ovarian cancerJournal of Clinical Oncology.  26:995-1005. 2008
    2008 Activator protein-1 contributes to high NaCL-induced increase in tonicity-responsive enhancer/osmotic response element-binding protein transactivating activityJournal of Biological Chemistry.  283:2554-2563. 2008
    2008 The aryl hydrocarbon receptor repressor is a putative tumor suppressor gene in multiple human cancersJournal of Clinical Investigation.  118:640-650. 2008
    2008 CON: Therapy for a patient with platinum-resistant/refractory ovarian cancer should not be selected based on results of an in vitro extreme drug sensitivity/resistance assayClinical Ovarian Cancer.  1:99-103. 2008
    2008 Classification of ovarian cancer: A genomic analysisAdvances in Experimental Medicine and Biology.  622:23-33. 2008
    2008 Clusterin interacts with paclitaxel and confer paclitaxel resistance in ovarian cancerNeoplasia : An International Journal for Oncology Research.  10:964-972. 2008
    2008 Highlights from the 2008 Annual Meeting of the American Association for Cancer Research.Gynecologic Oncology.  110:5-6. 2008
    2007 RASSF6 is a novel member of the RASSF family of tumor suppressorsOncogene.  26:6203-6211. 2007
    2007 Reactive oxygen species mediated apoptosis of esophageal cancer cells induced by marine triprenyl toluquinones and toluhydroquinonesMolecular Cancer Therapeutics.  6:2535-2543. 2007
    2007 EGF-R regulates MMP function in fibroblasts through MAPK and AP-1 pathwaysJournal of Cellular Physiology.  212:489-497. 2007
    2007 Workshop on imaging science development for cancer prevention and preemptionCancer Biomarkers.  3:1-33. 2007
    2007 Time for action: A "sea change" in treatment strategies for rare types of epithelial ovarian cancerGynecologic Oncology.  106:1-3. 2007
    2007 Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomasJournal of Clinical Oncology.  25:2281-2287. 2007
    2007 Identification of molecular markers and signaling pathway in endometrial cancer in Hong Kong Chinese women by genome-wide gene expression profilingOncogene.  26:1971-1982. 2007
    2007 Cell fate determination factor DACH1 inhibits c-Jun-induced contact-independent growthCell regulation.  18:755-767. 2007
    2007 Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinomaCancer Research.  67:1757-1768. 2007
    2007 Transcription factors as targets for cancer therapy: AP-1 a potential therapeutic targetCurrent Cancer Therapy Reviews.  3:1-6. 2007
    2007 Biomarkers of mucinous tumors of the ovaryDisease Markers.  23:389-396. 2007
    2007 Cell cycle and related proteinDisease Markers.  23:433-443. 2007
    2007 Disease Markers: PrefaceDisease Markers.  23:353. 2007
    2007 Etiology and pathogenesis of epithelial ovarian cancerDisease Markers.  23:367-376. 2007
    2007 PrefaceDisease Markers.  23:353. 2007
    2006 Biomarker Discovery in Epithelial Ovarian Cancer by Genomic ApproachesAdvances in Cancer Research.  96:1-22. 2006
    2006 IntroductionGynecologic Oncology.  103. 2006
    2006 Summary and discussion of session recommendationsGynecologic Oncology.  103. 2006
    2006 Expression profiling identifies altered expression of genes that contribute to the inhibition of transforming growth factor-β signaling in ovarian cancerCancer Research.  66:8404-8412. 2006
    2006 Roles of KLF6 and KLF6-SV1 in ovarian cancer progression and intraperitoneal disseminationClinical Cancer Research.  12:3730-3739. 2006
    2006 Expression profiling of mucinous tumors of the ovary identifies genes of clinicopathologic importanceClinical Cancer Research.  12:690-700. 2006
    2006 Thymosin β4 is a determinant of the transformed phenotype and invasiveness of S-adenosylmethionine decarboxylase-transfected fibroblastsCancer Research.  66:701-712. 2006
    2006 Biomarkers and clinical trial designGynecologic Oncology.  103:3-5. 2006
    2006 Ovarian cancer: Not a borderline issue!Cancer Biology and Therapy.  5:786-787. 2006
    2006 The future of phase II trialsGynecologic Oncology.  103:20-22. 2006
    2005 Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovaryCancer Research.  65:10602-10612. 2005
    2005 Identification of overexpression and amplification of ABCF2 in clear cell ovarian adenocarcinomas by cDNA microarray analysesClinical Cancer Research.  11:6880-6888. 2005
    2005 Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancerClinical Cancer Research.  11:6422-6430. 2005
    2005 Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancersClinical Cancer Research.  11:6300-6310. 2005
    2005 Cyclin A is a c-Jun target gene and is necessary for c-Jun-induced anchorage-independent growth in RAT1a cellsJournal of Biological Chemistry.  280:16728-16738. 2005
    2005 RRP22 is a farnesylated, nucleolar, ras-related protein with tumor suppressor potentialCancer Research.  65:3117-3125. 2005
    2005 p75-Ras-GRF1 is a c-Jun/AP-1 target protein: Its up regulation results in increased Ras activity and is necessary for c-Jun-induced nonadherent growth of Rat1a cellsMolecular and Cellular Biology.  25:3324-3337. 2005
    2004 Cyclin E amplification and overexpression in clear cell adenocarcinoma of the ovaryOncology.  67:291-299. 2004
    2004 Identification of DNA copy number changes in microdissected serous ovarian cancer tissue using a cDNA microarray platformCancer Genetics and Cytogenetics.  155:97-107. 2004
    2004 Whole genome expression profiling of advance stage papillary serous ovarian cancer reveals activated pathwaysOncogene.  23:8065-8077. 2004
    2004 Jun blockade of erythropoiesis: Role for repression of GATA-1 by HERP2Molecular and Cellular Biology.  24:7779-7794. 2004
    2004 Current challenges and opportunities for research on borderline ovarian tumorsHuman Pathology.  35:961-970. 2004
    2004 Reversible regulation of the transformed phenotype of ornithine decarboxylase- and ras-overexpressing cells by dominant-negative mutants of c-JunCancer Research.  64:3772-3779. 2004
    2004 DNA copy number abnormality of oral squamous cell carcinoma detected with cDNA array-based comparative genomic hybridization [4]Cancer Genetics and Cytogenetics.  151:90-92. 2004
    2004 HMG-I/Y is a c-Jun/activator protein-1 target gene and is necessary for c-Jun-induced anchorage-independent growth in Rat1a cellsCell Growth and Differentiation.  2:305-314. 2004
    2004 N-(4-hydroxyphenyl) retinamide (4HPR) enhances TRAIL-mediated apoptosis through enhancement of a mitochondrial-dependent amplification loop in ovarian cancer cell linesCell Death and Differentiation.  11:527-541. 2004
    2004 Synthesis of Flexible Sulfur-Containing Heteroarotinoids That Induce Apoptosis and Reactive Oxygen Species with Discrimination between Malignant and Benign CellsJournal of Medicinal Chemistry.  47:999-1007. 2004
    2004 Cyclooxygenase-2 expression predicts recurrence of cervical dysplasia following loop electrosurgical excision procedureGynecologic Oncology.  92:596-602. 2004
    2003 Choice of Normal Ovarian Control Influences Determination of Differentially Expressed Genes in Ovarian Cancer Expression Profiling StudiesClinical Cancer Research.  9:4811-4818. 2003
    2003 MAPK pathways mediate hyperoxia-induced oncotic cell death in lung epithelial cellsFree Radical Biology and Medicine.  35:978-993. 2003
    2003 Clinicopathological analysis of c-kit expression in carcinosarcomas and leiomyosarcomas of the uterine corpusGynecologic Oncology.  91:3-8. 2003
    2003 AP-1 complexes containing cJun and JunB cause cellular transformation of Ratla fibroblasts and share transcriptional targetsOncogene.  22:5619-5629. 2003
    2003 Cross-talk between JNK/SAPK and ERK/MAPK pathways: Sustained activation of JNK blocks ERK activation by mitogenic factorsJournal of Biological Chemistry.  278:26715-26721. 2003
    2003 Identification of cJun-responsive genes in Rat-1a cells using multiple techniques: Increased expression of stathmin is necessary for cJun-mediated anchorage-independent growthOncogene.  22:2710-2722. 2003
    2003 Cyclin E expression is a significant predictor of survival in advanced, suboptimally debulked ovarian epithelial cancers: A Gynecologic Oncology Group StudyCancer Research.  63:1235-1241. 2003
    2003 A link between histone deacetylase inhibitors and NF- kappaB signaling.Cell Cycle.  2:452-453. 2003
    2003 Biologic directed therapies in gynecologic oncologyCurrent Oncology Reports.  5:459-467. 2003
    2003 Restoration of an impaired TGF-beta1 autocrine growth-inhibitory circuit results in growth inhibition of ovarian epithelial cancer cells and complete inhibition of their tumorigenicityCancer Detection and Prevention.  27:380-388. 2003
    2003 The regulation of tumor suppressor genes by oncogenes.Methods in Molecular Biology.  222:269-292. 2003
    2002 Age-dependent changes in breast cancer hormone receptors and oxidant stress markersBreast Cancer Research and Treatment.  76:221-236. 2002
    2002 Retinoblastoma protein-mediated apoptosis after γ-irradiationJournal of Biological Chemistry.  277:44969-44979. 2002
    2002 CL100 expression is down-regulated in advanced epithelial ovarian cancer and its re-expression decreases its malignant potentialOncogene.  21:4435-4447. 2002
    2001 Ovarian tumors of low malignant potential: Can molecular biology solve this enigma?JNCI: Journal of the National Cancer Institute.  93:1122-1123. 2001
    2001 Abnormal fragile histidine triad (FHIT) expression in advanced cervical carcinoma: A poor prognostic factorCancer Research.  61:4382-4385. 2001
    2001 The c-Jun NH2-terminal protein kinase/AP-1 pathway is required for efficient apoptosis induced by vinblastineCancer Research.  61:4450-4458. 2001
    2001 In situ detection of unexpected patterns of mutant p53 gene expression in non-small cell lung cancersOncogene.  20:2579-2586. 2001
    2001 The role of p27 in endometrial carcinomaGynecologic Oncology.  81:242-246. 2001
    2000 Lovastatin induces apoptosis in a primitive neuroectodermal tumor cell line in association with RB down-regulation and loss of the G1 checkpointOncogene.  19:6082-6090. 2000
    2000 Ras uses the novel tumor suppressor RASSF1 as an effector to mediate apoptosisJournal of Biological Chemistry.  275:35669-35672. 2000
    2000 c-Jun activation-dependent tumorigenic transformation induced paradoxically by overexpression or block of S-adenosylmethionine decarboxylaseJournal of Cell Biology.  151:801-809. 2000
    2000 Alterations in the gene expression profile of MCF-7 breast tumor cells in response to c-JunInternational Journal of Cancer.  88:180-190. 2000
    2000 TNF-α gene expression in macrophages: Regulation by NF-κB is independent of c-Jun or C/EBPβJournal of Immunology.  164:4277-4285. 2000
    2000 Expression of human papilloma virus E7 protein causes apoptosis and inhibits DNA synthesis in primary hepatocytes via increased expression of p21(Cip-1WAF1/MDA6)Journal of Biological Chemistry.  275:18-28. 2000
    2000 Activator protein-1 mediates induced but not basal epidermal growth factor receptor gene expression.Molecular Medicine.  6:17-27. 2000
    2000 Age-specific survival of women with endometrioid adenocarcinoma of the uterusGynecologic Oncology.  79:86-89. 2000
    2000 Endocervical cancer is associated with an increase in the ligands and receptors for transforming growth factor-β and a contrasting decrease in p27(Kip1 1)Gynecologic Oncology.  78:113-122. 2000
    2000 Inhibition of the mitogen activated protein kinase pathway potentiates radiation-induced cell killing via cell cycle arrest at the G2/M transition and independently of increased signaling by the JNK/c-Jun pathway.International Journal of Oncology.  16:413-422. 2000
    2000 p27 and cyclin D1 abnormalities in uterine papillary serous carcinomaGynecologic Oncology.  77:439-445. 2000
    1999 cJun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotypeOncogene.  18:6063-6070. 1999
    1999 Abnormal Fhit expression in malignant and premalignant lesions of the cervixCancer Research.  59:5270-5274. 1999
    1999 c-Jun triggers apoptosis in human vascular endothelial cellsCirculation Research.  85:387-393. 1999
    1999 JunB forms the majority of the AP-1 complex and is a target for redox regulation by receptor tyrosine kinase and G protein-coupled receptor agonists in smooth muscle cellsJournal of Biological Chemistry.  274:6003-6010. 1999
    1999 Frequent loss of KAI1 expression in squamous and lymphoid neoplasms: An immunohistochemical study of archival tissuesAmerican Journal of Pathology.  154:1665-1671. 1999
    1998 Inhibition of the mitogen activated protein (MAP) kinase cascade potentiates cell killing by low dose ionizing radiation in A431 human squamous carcinoma cellsOncogene.  16:2787-2796. 1998
    1998 Identification of domains of c-Jun mediating androgen receptor transactivationOncogene.  16:2001-2009. 1998
    1998 Retinoic acid receptor β expression and growth inhibition of gynecologic cancer cells by the synthetic retinoid N-(4-hydroxyphenyl) retinamideJNCI: Journal of the National Cancer Institute.  90:597-605. 1998
    1998 PACAP(6-38) inhibits the growth of prostate cancer cellsCancer Letters.  125:131-139. 1998
    1998 Alterations in differentiation and apoptosis induced by bufalin in cJun overexpressing U-937 cellsInternational Journal of Oncology.  12:403-409. 1998
    1998 AP1 regulation of proliferation and initiation of apoptosis in erythropoietin-dependent erythroid cellsMolecular and Cellular Biology.  18:3699-3707. 1998
    1998 RRR-α-tocopheryl succinate induction of prolonged activation of c-jun amino-terminal kinase and c-jun during induction of apoptosis in human MDA- MB-435 breast cancer cellsMolecular Carcinogenesis.  22:247-257. 1998
    1998 The Ras/Rac1/Cdc42/SEK/JNK/c-Jun cascade is a key pathway by which agonists stimulate DNA synthesis in primary cultures of rat hepatocytesCell regulation.  9:561-573. 1998
    1998 The roles of signaling by the p42/p44 mitogen-activated protein (MAP) kinase pathway; A potential route to radio- and chemo-sensitization of tumor cells resulting in the induction of apoptosis and loss of clonogenicityLeukemia.  12:1843-1850. 1998
    1998 Tumor necrosis factor alpha gene regulation: Enhancement of C/EBPβ- induced activation by c-JunMolecular and Cellular Biology.  18:2815-2824. 1998
    1997 Involvement of activator protein-1 (AP-1) in induction of apoptosis by Vitamin E succinate in human breast cancer cellsMolecular Carcinogenesis.  19:180-190. 1997
    1997 Breast cancer cells have lower activating protein 1 transcription factor activity than normal mammary epithelial cells1Cancer Research.  57:3046-3054. 1997
    1997 PACAP hybrid: A new PACAP receptor antagonistLife Sciences.  61:631-639. 1997
    1997 FHIT gene expression in human ovarian, endometrial, and cervical cancer cell linesCancer Research.  57:2112-2115. 1997
    1997 The Jun kinase/stress-activated protein kinase pathway functions to regulate DNA repair and inhibition of the pathway sensitizes tumor cells to cisplatinJournal of Biological Chemistry.  272:14041-14044. 1997
    1997 Analysis of Ki-ras, p53, and MDM2 genes in uterine leiomyomas and leiomyosarcomasGynecologic Oncology.  65:330-335. 1997
    1997 Coordinate regulation of stress- and mitogen-activated protein kinases in the apoptotic actions of ceramide and sphingosineMolecular Pharmacology.  52:935-947. 1997
    1997 Discoveries in the cell cycle and ovarian cancerGynecologic Oncology.  64:187-188. 1997
    1997 Molecular characterization of adenocarcinoma of the cervixGynecologic Oncology.  64:242-251. 1997
    1996 Bryostatin 1 potentiates 1-[β-D-arabinofuranosyl] cytosine-mediated antiproliferative effects in c-jun dominant-negative human myeloid leukemia cells (U937/TAM67) through a nonapoptotic mechanismMolecular and cellular differentiation.  4:247-262. 1996
    1996 Regulation of nuclear oncogenes expressed in lung cancer cell linesJournal of Cellular Biochemistry.  62:218-227. 1996
    1996 Dominant-negative mutants of cJun inhibit AP-1 activity through multiple mechanisms and with different potenciesCell Growth and Differentiation.  7:1013-1021. 1996
    1996 Effect of 1-β-D-arabinofuranosylcytosine on apoptosis and differentiation in human monocytic leukemia cells (U937) expressing a c-jun dominant-negative mutant protein (TAM67)Cell Growth and Differentiation.  7:603-613. 1996
    1996 Use of transcription factors as agents and targets for drug developmentOncology.  10:1532-1538. 1996
    1996 Breast cancer growth is inhibited by vasoactive intestinal peptide (VIP) hybrid, a synthetic VIP receptor antagonistCancer Research.  56:3486-3489. 1996
    1996 Role of c-jun in human myeloid leukemia cell apoptosis induced by pharmacological inhibitors of protein kinase CMolecular Pharmacology.  49:788-795. 1996
    1996 The inhibitory activity of a transdominant c-jun mutant fused to the ligand binding domain of the estrogen receptorOncogene.  12:1043-1053. 1996
    1996 The human papillomavirus type 16 E7 gene product interacts with and trans-activates the AP1 family of transcription factorsEMBO Journal.  15:1950-1960. 1996
    1996 Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosisNature.  380:75-79. 1996
    1996 Activation and inhibition of the AP-1 complex in human breast cancer cellsMolecular Carcinogenesis.  15:215-226. 1996
    1996 Altered cJun expression: An early event in human lung carcinogenesisCancer Research.  56:305-315. 1996
    1996 PACAP stimulates c-fos mRNAs in small cell lung cancer cellsLife Sciences.  59:307-313. 1996
    1996 Regulation of nuclear oncogenes expressed in lung cancer cell linesJournal of Cellular Biochemistry.  62:218-227. 1996
    1995 Regulation of urokinase-type plasminogen activator expression by the v-mos oncogeneOncogene.  11:2638-2648. 1995
    1995 Translational research and epithelial carcinogenesis: Molecular diagnostic assays now - molecular screening assays soon?JNCI: Journal of the National Cancer Institute.  87:1041-1043. 1995
    1995 Abnormal expression of the retinoblastoma gene in ovarian neoplasms and correlation to P53 and K-ras mutationsGynecologic Oncology.  58:307-311. 1995
    1995 Bombesin stimulates c-fos and c-jun mRNAs in small cell lung cancer cellsPeptides.  16:289-292. 1995
    1995 Negative transcriptional regulation of the interferon-γ promoter by glucocorticoids and dominant negative mutants of c-JunJournal of Biological Chemistry.  270:12548-12556. 1995
    1995 c‐jun and multistage carcinogenesis: Association of overexpression of introduced c‐jun with progression toward a neoplastic endpoint in mouse JB6 cells sensitive to tumor promoter‐induced transformationMolecular Carcinogenesis.  13:27-36. 1995
    1994 Transformation by Raf and other oncogenes renders cells differentially sensitive to growth inhibition by a dominant negative c-jun mutantOncogene.  9:3493-3498. 1994
    1994 The molecular genetics of gyn malignancies.Oncology.  8:63-78. 1994
    1994 Dominant negative mutant of c-Jun inhibits NF-AT transcriptional activity and prevents IL-2 gene transcriptionJournal of Immunology.  153:2046-2051. 1994
    1994 Mechanism of action of a dominant-negative mutant of c-JunOncogene.  9:791-799. 1994
    1994 Blocking of tumor promoter-induced AP-1 activity inhibits induced transformation in JB6 mouse epidermal cellsProceedings of the National Academy of Sciences.  91:609-613. 1994
    1994 Constitutive cJun expression induces partial macrophage differentiation in U-937 cellsCell Growth and Differentiation.  5:439-446. 1994
    1994 Stable expression of a c-JUN deletion mutant in two malignant mouse epidermal cell lines blocks tumor formation in nude miceCell Growth and Differentiation.  5:9-16. 1994
    1993 The molecular biology of lung cancer: application to early detection and prevention.Oncology.  7:19-31. 1993
    1993 Suppression of oncogene-induced transformation by a deletion mutant of c-junOncogene.  8:877-886. 1993
    1993 Cooperation between retinoic acid and phorbol esters enhances human teratocarcinoma differentiationDifferentiation.  54:115-122. 1993
    1993 Early detection of lung cancerSeminars in Oncology.  20:374-382. 1993
    1993 p53 and Ki-ras Gene Mutations in Epithelial Ovarian NeoplasmsCancer Research.  53:3103-3108. 1993
    1992 Candidate biomarkers for application as intermediate end points of lung carcinogenesis.Journal of Cellular Biochemistry -Supplement-.  16 G:183-186. 1992
    1992 Application of molecular genetics to the early diagnosis and screening of lung cancerCancer Research.  52. 1992
    1992 Activation domains of L-Myc and c-Myc determine their transforming potencies in rat embryo cellsMolecular and Cellular Biology.  12:3130-3137. 1992
    1992 Candidate biomarkers for applications as intermediate end points of lung carcinogenesisJournal of Cellular Biochemistry.  50:183-186. 1992
    1992 Early events in the neoplastic transformation of respiratory epithelium.JNCI Monographs.  31-37. 1992
    1992 Growth factors and other targets for rational application as intervention agentsAdvances in human genetics.  320:81-88. 1992
    1992 Rational targets for the early detection of lung cancer.JNCI Monographs.  183-190. 1992
    1992 Regions within the c-Myc protein that are necessary for transformation are also required for inhibition of differentiation of murine erythroleukemia cells.Cell Growth and Differentiation.  3:183-190. 1992
    1991 Occurrence of p53 gene abnormalities in gastric carcinoma tumors and cells linesJNCI: Journal of the National Cancer Institute.  83:938-943. 1991
    1991 A complex pattern of translational initiation and phosphorylation in L-myc proteinsOncogene.  6:371-378. 1991
    1991 Oncogenic and transcriptional cooperation with Ha-Ras requires phosphorylation of c-Jun on serines 63 and 73Nature.  354:494-496. 1991
    1991 The role of jun and fos gene family members in 12-O-tetradecanoylphorbol-13-acetate induced hemopoietic differentiation.Cell Growth and Differentiation.  2:475-482. 1991
    1991 The transactivating domain of the c-Jun proto-oncoprotein is required for cotransformation of rat embryo cellsMolecular and Cellular Biology.  11:6286-6295. 1991
    1990 Expression of the atrial natriuretic factor gene in small cell lung cancer tumors and tumor cell linesJNCI: Journal of the National Cancer Institute.  82:305-310. 1990
    1989 A transfected L-myc gene can substitute for c-myc in blocking murine erythroleukemia differentiationMolecular and Cellular Biology.  9:2734-2737. 1989
    1989 Deregulated expression of human c-jun transforms primary rat embryo cells in cooperation with an activated c-Ha-ras gene and transforms Rat-1a cells as a single geneProceedings of the National Academy of Sciences.  86:2257-2261. 1989
    1989 Genetic changes in the pathogenesis of lung cancerAnnual Review of Medicine.  40:305-317. 1989
    1989 Transcription factors and recessive oncogenes in the pathogenesis of human lung cancerInternational Journal of Cancer.  44:32-34. 1989
    1989 Transcription factors and recessive oncogenes in the pathogenesis of human lung cancer.International Journal of Cancer Supplement.  4:32-34. 1989
    1989 p53: A frequent target for genetic abnormalities in lung cancerScience.  246:491-494. 1989
    1988 L-myc cooperates with ras to transform primary rat embryo fibroblasts.Molecular and Cellular Biology.  8:2668-2673. 1988
    1988 Molecular genetics of lung cancerSeminars in Oncology.  15:226-235. 1988
    1988 Multiple mechanisms for transcriptional regulation of the myc gene family in small-cell lung cancerMolecular and Cellular Biology.  8:3373-3381. 1988
    1988 Structure and expression of the human L-myc gene reveal a complex pattern of alternative mRNA processingMolecular and Cellular Biology.  8:186-195. 1988
    1988 The human L-myc gene encodes multiple nuclear phosphoproteins from alternatively processed mRNAsMolecular and Cellular Biology.  8:4381-4388. 1988
    1986 Chromosomal deletion, gene amplification, alternative processing, and autocrine growth factor production in the pathogenesis of human lung cancer.Princess Takamatsu symposia.  17:109-122. 1986

    Book

    Year Title Altmetric
    2017 Translational Advances in Gynecologic Cancers 2017
    2017 Translational Advances in Gynecologic Cancers: Introduction 2017
    2014 Uncommon Gynecologic Cancers 2014

    Chapter

    Year Title Altmetric
    2017 Ovarian Cancer Genomics.  19-34. 2017
    2015 Molecular biology of gynecologic cancers 2015
    2015 Molecular Biology of Gynecologic Cancers 2015
    2013 Molecular pathogenesis of gynecologic cancers.  30-59. 2013
    2012 Ovarian cancer.  381-401. 2012
    2011 Discovery of novel targets.  35-50. 2011
    2008 Whole-Genome Expression Profiling of Papillary Serous Ovarian Cancer: Activated Pathways, Potential Targets, and Noise.  149-164. 2008
    2007 Molecular profiling in ovarian cancer.  63-82. 2007

    Education And Training

  • Doctor of Medicine, Yeshiva University 1982
  • Doctor of Science or Mathematics in Microbiology and Immunology, Yeshiva University 1982
  • Master of Sciences or Mathematics in Microbiology and Immunology, Yeshiva University 1982
  • Bachelor of Science or Mathematics in Biology, Rensselaer Polytechnic Institute 1976
  • Massachusetts General Hospital, Internship 1983
  • Massachusetts General Hospital, Residency 1985
  • National Cancer Institute, Postdoctoral Fellowship 1988
  • Full Name

  • Michael J. Birrer